Vivani Medical, Inc.

Vivani Medical, Inc. is a clinical stage biopharmaceutical company that develops miniature, ultra long-acting subdermal drug implant candidates. The company utilizes its proprietary NanoPortal™ technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop and potentially commercialize drug implant candidates, either independently or in collaboration with pharmaceutical company partners. These candidates aim to address leading causes of poor clinical outcomes in chronic disease treatment, such as medication non-adherence, drug tolerability, and administration challenges. According to the U.S. Centers for Disease Control and Prevention, adherence refers to how well an individual's behavior, including taking medications, aligns with healthcare provider recommendations. Approximately 50% of patients do not or cannot take their medicine as prescribed, a statistic applicable to both daily oral and weekly injectable medicines. For instance, a recent study indicated that 64% of patients taking Wegovy® (semaglutide injection) discontinue treatment within the first year, increasing to 76% by the second year. GLP-1 discontinuation can lead to failure in achieving target outcomes and a rapid reversal of health benefits for most patients. Vivani is developing a portfolio of miniature, ultra long-acting subdermal drug implant candidates based on its NanoPortal technology. These implants are designed to guarantee medication adherence by delivering therapeutic drug levels for up to six months or longer, unlike most oral and injectable medicines. The NanoPortal implant technology has the potential to allow patients to maintain continuous and therapeutic drug exposure levels with convenient once or twice yearly administration, and the option to stop therapy at any time by removing the implant.